Shop by goal

Popular compounds

GHK-Cu

GLP1-RC-RT

Research resources

Retatrutide vs Tirzepatide

Q: What is the difference between Retatrutide and Tirzepatide?

Retatrutide is a GLP-1 compound (Subcutaneous route) - Triple GIP / GLP-1 / glucagon receptor agonist. Phase 3 investigational — research use only. Tirzepatide is a GLP-1 compound (Subcutaneous route) - Dual GIP / GLP-1 receptor agonist. Once-weekly subcutaneous. 20-week titration is the FDA-label maximum-tolerated path.

Q: Which has a longer half-life, Retatrutide or Tirzepatide?

Retatrutide has the longest published plasma half-life (~6.0 days (144 h)), compared with Tirzepatide (~5.0 days (120 h)).

Q: How often is each compound dosed in the research literature?

Retatrutide: once weekly at a published dose range of 2–12 mg; Tirzepatide: once weekly at a published dose range of 2.5–15 mg. These are descriptive reference parameters, not dosing recommendations.

Q: Can you buy Retatrutide and Tirzepatide for research use?

Yes - Retatrutide, Tirzepatide are available from New-U Research Compounds as lab-verified (>99% HPLC) compounds.

Published pharmacokinetic and receptor-characteristic comparison with primary-source references.

Updated August 2026 Research use only

GLP1-RC-RT

Retatrutide

Triple receptor agonist

GLP-1R · GIPR · GCGR

GLP1-RC-TZ

Tirzepatide

Dual receptor agonist

GLP-1R · GIPR

Key research differences

Retatrutide Tirzepatide Receptor profile GLP-1R · GIPR · GCGR GLP-1R · GIPR Development status Investigational Approved therapeutic molecule Published half-life ~6.0 days (144 h) ~5.0 days (120 h) Research distinction Adds glucagon receptor agonism Dual incretin agonism

Published research parameters

Retatrutide LY3437943 View Retatrutide → Tirzepatide Mounjaro, Zepbound View Tirzepatide → Receptor profile GLP-1R · GIPR · GCGR GLP-1R · GIPR Class Triple receptor agonist Dual receptor agonist Plasma half-life ~6.0 days (144 h) ~5.0 days (120 h) Time to Cmax 36 h 36 h Development status Investigational Approved therapeutic molecule Study context Peer-reviewed human PK Regulatory label PK Primary publications Jastreboff AM et al., NEJM 389:514 (Phase 2 results) (2023) FDA Mounjaro USPI — half-life ~5 days (120 h) (2024) Summary Triple GIP / GLP-1 / glucagon receptor agonist. Phase 3 investigational — research use only. Dual GIP / GLP-1 receptor agonist. Once-weekly subcutaneous. 20-week titration is the FDA-label maximum-tolerated path.

View published study parameters

Retatrutide LY3437943 View Retatrutide → Tirzepatide Mounjaro, Zepbound View Tirzepatide → Route in published studies Subcutaneous Subcutaneous Published study interval Once weekly Once weekly Published dose range 2–12 mg 2.5–15 mg Published study regimen 2 → 4 → 6 → 8 → 12 mg 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg

Source references

Jastreboff AM et al.

New England Journal of Medicine · 2023

Jastreboff AM et al., NEJM 389:514 (Phase 2 results) (2023)

Rosenstock J et al.

The Lancet · 2023

Rosenstock J et al., Lancet 402:529 (titration arms) (2023)

FDA Mounjaro USPI — half-life ~5 days (120 h)

FDA prescribing information · 2024

FDA Mounjaro USPI — half-life ~5 days (120 h) (2024)

SURPASS-2 trial — NEJM 385:503

New England Journal of Medicine · 2021

SURPASS-2 trial — NEJM 385:503 (2021)

Urva S et al.

Clinical Pharmacokinetics · 2022

Urva S et al., Clin Pharmacokinet 61:1057 (Tmax 24–72 h) (2022)

Frequently asked questions

What is the difference between Retatrutide and Tirzepatide?

Which has a longer half-life, Retatrutide or Tirzepatide?

How often is each compound dosed in the research literature?

Can you buy Retatrutide and Tirzepatide for research use?

Continue researching

Research guides, current certificates and related research for Retatrutide and Tirzepatide. Research use only.

Research guide Retatrutide research guide Published experimental work characterises agonist activity across GLP-1R, GIPR and GCGR, with structural modifications investigated for… Read the guide →

Research guide Tirzepatide research guide Published experimental work characterises dual GIPR / GLP-1R agonist activity with imbalanced agonism, plus an albumin-binding structural… Read the guide →

Analytical evidence View the Retatrutide COA Current batch purity and identity testing, 2026-07-24. View the COA →

Analytical evidence View the Tirzepatide COA Current batch purity and identity testing, 2026-05-27. View the COA →

Compare Compare Retatrutide and Semaglutide Retatrutide vs Semaglutide: mechanism, receptor profile and specifications side by side. Compare →

Continue research

← Compare other compounds

PRECISION. PURITY. PERFORMANCE.

Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research